-

Jury Finds in Favor of Monsanto in Philadelphia Trial

Young decision marks 14th favorable outcome in last 20 trials for Company

WHIPPANY, N.J.--(BUSINESS WIRE)--Today, the jury reached a verdict in the Young Roundup™ product liability trial before Judge Angelo Foglietta in the Philadelphia Court of Common Pleas.

In response to the decision, Monsanto issued the following statement:

“The jury’s verdict in favor of the Company marks the 14th favorable outcome in the last 20 trials and validates the Company’s strategy of taking cases to trial based on strong scientific and regulatory evidence. The verdict makes clear that the plaintiff failed to prove that Roundup™ was the cause of the injuries alleged in this case, consistent with the scientific evidence and the consensus of regulatory bodies and their scientific assessments worldwide. While we have great sympathy for anyone who suffers a loss or injury, the science proves that Roundup™ is not carcinogenic.

“This verdict follows the favorable ruling from the Third Circuit Court of Appeals in Schaffner v. Monsanto, which unanimously held that the state-based failure-to-warn claims central to these cases are expressly preempted by the federal law, since the U.S. EPA has repeatedly concluded the product does not cause cancer and approved the product label without any such warning. The Company is actively taking steps to apply the Schaffner ruling to other Roundup™ cases and looks forward to presenting its arguments, as fully embraced by the Third Circuit, at trial courts, appellate courts, and the U.S. Supreme Court.

“Additionally, outside the courtroom, we will continue supporting legislation at the state and federal level alongside hundreds of agricultural organizations to ensure that any pesticide reviewed and registered by the U.S. EPA – and sold under a label consistent with the EPA’s determinations – is sufficient to satisfy requirements for health and safety warnings. Without legislative certainty, the litigation industry will continue to target crop protection tools that have been deemed safe by experts at the U.S. EPA.

“We continue to stand fully behind the safety of Roundup™ products – critical tools that farmers rely on to produce affordable food and feed the world.”

Contacts

Media
Brian Leake
Brian.Leake@Bayer.com
(314) 370.3285

Monsanto


Release Versions

Contacts

Media
Brian Leake
Brian.Leake@Bayer.com
(314) 370.3285

More News From Monsanto

Court Grants Final Approval to Roundup™ Class Settlement

ST. LOUIS--(BUSINESS WIRE)--Today, a Missouri state court granted final approval of the U.S. nationwide class settlement designed to resolve current and future Roundup™ claims alleging non-Hodgkin's lymphoma (NHL) injuries through a long-term claims program. The Court’s final approval order is subject to appeal. The class settlement, combined with the U.S. Supreme Court’s favorable ruling in June in the Durnell case, are mutually reinforcing pillars in the company’s multipronged strategy design...

Bayer’s SUNHARBO® (asundexian) Now Available in the United States

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that SUNHARBO® (asundexian), 50 mg tablets, is now available to order in the United States. Hospitals, health systems and pharmacies have immediate access to order the product for inventory. SUNHARBO is the first approved Factor XIa inhibitor in the U.S. and represents the first in a new class of medicine.1 SUNHARBO is indicated in combination with antiplatelet therapy to reduce the risk of stroke in adults with recent non-cardioembolic isc...

Bayer’s SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Recent Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Bayer’s SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Recent Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, in Combination With Antiplatelet Therapy Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved SUNHARBO® (asundexian), 50 mg tablets, a first-in-class, once daily, Factor XIa inhibitor indicat...
Back to Newsroom